| Code | CSB-RA33255B1GMY |
| Size | US$210 |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
The SARS-CoV-2 nucleocapsid protein serves as one of the most abundant viral proteins during infection, playing essential roles in viral RNA packaging, replication, and host cell interactions. Its high immunogenicity and conservation across viral variants have established it as a primary target for COVID-19 diagnostics, seroprevalence studies, and investigations into viral pathogenesis.
This recombinant monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein offers researchers the reproducibility and consistency that recombinant technology provides. As a sequence-defined reagent produced from a single clone, it eliminates the lot-to-lot variability that can compromise longitudinal studies or assay development efforts. The engineered format combines a mouse single-chain variable fragment with a human IgG1 Fc domain, creating a well-characterized binding molecule with predictable behavior across experiments.
The direct HRP conjugation streamlines immunoassay workflows by eliminating secondary antibody incubation steps, reducing protocol time and potential background signal. Functional ELISA validation demonstrates strong binding activity against recombinant SARS-CoV-2 nucleoprotein, with an EC50 of 188.35 ng/ml when tested against immobilized antigen. The recommended working dilution range of 1:10,000 to 1:50,000 reflects the conjugate's sensitivity, allowing researchers to optimize signal-to-noise ratios for their specific assay conditions.
Supplied in a glycerol-based buffer system for stability at frozen storage temperatures, this antibody is well-suited for researchers developing or performing ELISA-based detection of SARS-CoV-2 nucleocapsid protein in diagnostic applications, vaccine response monitoring, or basic virology research exploring coronavirus biology and host-pathogen interactions.
There are currently no reviews for this product.